Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,019 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Experimental therapy Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool

NCT05706311
View directory record Official record
Conditions
Opioid Abuse, Prescription Opioid Abuse
Interventions
Clinical Decision Support Tool (Moderate Risk), Clinical Decision Support Tool (High Risk), Standard of Care
Behavioral · Other
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Cincinnati, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 26, 2026, 9:30 PM EDT
Active, not recruiting Not applicable Interventional

Accelerated High-Dose tDCS for Depression

NCT07226011
View directory record Official record
Conditions
Major Depression, Major Depression Disorders
Interventions
Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 26, 2026, 9:30 PM EDT
Not yet recruiting Not applicable Interventional

Interacting With Children Training for Undergraduates

NCT07696611
View directory record Official record
Conditions
Child-Adult Interaction Training
Interventions
CARE Training, Psychoeducation Training
Behavioral
Lead sponsor
Auburn University
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 1 Interventional

Designing and Testing a Family Therapy for Adolescent Depression

NCT00867919
View directory record Official record
Conditions
Depression
Interventions
Behavioral Family Treatment, Community-based treatment as usual
Behavioral · Other
Lead sponsor
Oregon Research Institute
Other
Eligibility
14 Years to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 18, 2013 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

NCT01211483
View directory record Official record
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
U3-1287, Erlotinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
14
States / cities
Glendale, Arizona • Scottsdale, Arizona • Anaheim, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents

NCT01319812
View directory record Official record
Conditions
Peripheral Artery Disease, Peripheral Vascular Disease
Interventions
Astron Stents, Pulsar Stents
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
33
States / cities
Fremont, California • New Haven, Connecticut • Washington D.C., District of Columbia + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Not applicable Interventional

Healthy Directions After Lung Surgery Pilot

NCT02135211
View directory record Official record
Conditions
Carcinoma, Non Small Cell Lung
Interventions
Lifestyle counseling
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

Care4Today v2.0 Application for Improving Adherence to HIV Medications

NCT02001064
View directory record Official record
Conditions
HIV, AIDS
Interventions
Care4Today v2.0 mobile application + electronic monitoring of adherence
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 26, 2026, 9:30 PM EDT
Recruiting Phase 4 Interventional

Anti-Inflammatory Challenge in Schizophrenia

NCT05823532
View directory record Official record
Conditions
Schizophrenia
Interventions
Infliximab, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 26, 2026, 9:30 PM EDT
Recruiting Not applicable Interventional

Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer

NCT07643012
View directory record Official record
Conditions
Endometrial Cancer
Interventions
MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT)
Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 26, 2026, 9:30 PM EDT
Recruiting Phase 1 Interventional

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

NCT07222267
View directory record Official record
Conditions
Breast Cancer, Advanced Solid Tumor
Interventions
BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
6
States / cities
Birmingham, Alabama • New Haven, Connecticut • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 26, 2026, 9:30 PM EDT
Active, not recruiting Phase 2 Interventional

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

NCT04777071
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography, Magnetic Resonance Imaging, Bone Scan, Electronic Health Record Review
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 26, 2026, 9:30 PM EDT
Suspended Phase 1 Interventional

A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC

NCT03392064
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
AMG 119
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 26, 2026, 9:30 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults

NCT01345864
View directory record Official record
Conditions
Healthy
Interventions
Scopolamine + Donepezil Placebo + PF-04995274 Placebo, Scopolamine + Donepezil 5 mg + PF-04995274 Placebo, Scopolamine + Donepezil 10mg + PF-04995274 Placebo, Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg, Scopolamine + Donepezil Placebo + PF-04995274 15 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 26, 2026, 9:30 PM EDT
Active, not recruiting Phase 1 Interventional

Surgical Nivolumab And Ipilimumab For Recurrent GBM

NCT04606316
View directory record Official record
Conditions
Glioblastoma, GBM, Glioblastoma Multiforme, Grade IV Astrocytoma
Interventions
Nivolumab-Placebo, Nivolumab, Ipilimumab-Placebo, Ipilimumab, Surgery
Drug · Procedure
Lead sponsor
Gilbert Youssef
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options

NCT03602885
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Colorectal Cancer
Interventions
Usual chemotherapy education (CE), Chemotherapy education intervention (CEI)
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Tampa, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

NCT03063632
View directory record Official record
Conditions
Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7, Unresectable Synovial Sarcoma
Interventions
Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Palo Alto, California • Miami, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 26, 2026, 9:30 PM EDT
Not listed Phase 4 Interventional

The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection

NCT02307006
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Ceftaroline, Cefazolin / Vancomycin
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Cincinnati, Ohio • West Chester, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

NCT01382238
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
Dolutegravir 50 mg tablet, Dolutegravir 50 mg oral granules
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Oct 26, 2026, 9:30 PM EDT
Recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy

NCT07332143
View directory record Official record
Conditions
PTSD
Interventions
psilocybin, Supportive Therapy, Prolonged Exposure Therapy
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 26, 2026, 9:30 PM EDT
Withdrawn Not applicable Interventional

The Utilization of Yoga as a Therapeutic Tool to Promote Physical Activity Behavior Change and Improved Postural Control in Individuals With Multiple Sclerosis

NCT04113135
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Yoga, Control
Other
Lead sponsor
Winston Salem State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 26, 2026, 9:30 PM EDT
Not listed Not applicable Interventional

Wrist-worn Sensors for Tele-Rehabilitation of the Hemiparetic Upper Extremity

NCT03431025
View directory record Official record
Conditions
Stroke, Hemiparesis
Interventions
Wearable sensors and biofeedback
Device
Lead sponsor
BioSensics
Industry
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring

NCT04606134
View directory record Official record
Conditions
Acne Scars - Mixed Atrophic and Hypertrophic
Interventions
Hybrid fractional laser, Alastin Regenerating Skin Nectar with TriHex Technology, Cetaphil face cream
Device · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)

NCT02091206
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome
Interventions
GWP42003-P 5 mg/kg/day Dose, Placebo control, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
4 Years to 10 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 26, 2026, 9:30 PM EDT